	US 12,215,153 B1
	Anti-receptor expressed on lymphoid tissues (RELT) recombinant monoclonal antibody and preparation method and use thereof
Congyi Wang, Wuhan (CN); Shanjie Rong, Wuhan (CN); Fei Sun, Wuhan (CN); Chunliang Yang, Wuhan (CN); and Jiahui Luo, Wuhan (CN)
Assigned to TONGJI HOSPITAL, TONGJI MEDICAL COLLEGE OF HUST, Wuhan (CN)
Filed by TONGJI HOSPITAL, TONGJI MEDICAL COLLEGE OF HUST, Wuhan (CN)
Filed on Jun. 17, 2024, as Appl. No. 18/745,750.
Claims priority of application No. 202311101875.6 (CN), filed on Aug. 30, 2023.
Int. Cl. C07K 16/00 (2006.01); A61P 3/10 (2006.01); C07K 16/28 (2006.01); C07K 16/46 (2006.01); A61K 39/00 (2006.01)

CPC C07K 16/2803 (2013.01) [A61P 3/10 (2018.01); A61K 2039/505 (2013.01); C07K 2317/14 (2013.01); C07K 2317/76 (2013.01)]

2 Claims

1. An anti-receptor expressed on lymphoid tissues (RELT) recombinant monoclonal antibody, comprising a heavy chain variable region and a light chain variable region, wherein the amino acid sequence of the heavy chain variable region is set forth in SEQ ID NO: 4; the amino acid sequence of the light chain variable region is set forth in SEQ ID NO: 5; and

the anti-RELT recombinant monoclonal antibody has a biological activity of neutralizing a function of RELT.